Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
-
ORGANIZATION JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
-
REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
-
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
-
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
-
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
-
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
-
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
-
REGULATORY Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
-
REGULATORY Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
-
BUSINESS Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
-
REGULATORY MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
-
BUSINESS AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
December 11, 2017
-
REGULATORY Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
-
REGULATORY Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
-
REGULATORY (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
-
REGULATORY CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
-
BUSINESS Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…